In patients with recent ACS and uncontrolled dyslipidemia, alirocumab reduced MACE regardless of previous CABG.

Journal Article

Full Text

Duke Authors

Cited Authors

  • Carnicelli, AP; Granger, CB

Published Date

  • January 21, 2020

Published In

Volume / Issue

  • 172 / 2

Start / End Page

  • JC3 -

PubMed ID

  • 31958817

Pubmed Central ID

  • 31958817

Electronic International Standard Serial Number (EISSN)

  • 1539-3704

Digital Object Identifier (DOI)

  • 10.7326/ACPJ202001210-003

Language

  • eng

Conference Location

  • United States